Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 11/20 | 0.36 |
| ▸ | SMO | Q99835 | 3/20 | 0.35 |
| ▸ | WHR1 | P49842 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 5/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.34 |
| ▸ | KIT | P10721 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4679265 | 1.00 | KDM4E (0.40) | KDM4EHSD17B10GRM4KDRSMO | |
| SCHEMBL1929839 | 0.86 | KDR (0.42) | KDM4EHSD17B10GRM4KDRFLT1 | |
| SCHEMBL1930948 | 0.85 | KDR (0.42) | KDM4EHSD17B10GRM4KDRWHR1 | |
| SCHEMBL4681363 | 0.85 | KDR (0.42) | KDM4EHSD17B10GRM4KDRWHR1 | |
| SCHEMBL1382638 | 0.84 | GRM4 (0.38) | KDM4EHSD17B10GRM4WHR1 | |
| SCHEMBL6226746 | 0.84 | GRM4 (0.38) | KDM4EHSD17B10GRM4WHR1 | |
| SCHEMBL1930868 | 0.84 | KDR (0.35) | KDM4EHSD17B10KDRSMOFLT1 | |
| SCHEMBL4680006 | 0.84 | KDR (0.35) | KDM4EHSD17B10KDRSMOFLT1 | |
| SCHEMBL4740445 | 0.79 | KDR (0.33) | KDRSMOFLT1PDGFRBKIT | |
| SCHEMBL4740449 | 0.79 | KDR (0.33) | KDRSMOFLT1PDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7399761-B2 | Phthalazine derivatives with angiogenesis inhibiting activity | NOVARTIS AG (CH) | 2008-07-15 | — | — | US | claimed |
| EP-1387836-B1 | PHTHALAZINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 2008-04-23 | — | — | EP | claimed |
| US-20040180899-A1 | Phthalazine derivatives with angiogenesis inhibiting activity | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | claimed |
| EP-1387836-A1 | PHTHALAZINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | Novartis AG (CH) | 2004-02-11 | — | — | EP | claimed |
| WO-2002090346-A1 | PHTHALAZINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 2002-11-14 | — | — | WO | claimed |
| US-8034814-B2 | Phthalazine derivatives with angiogenesis inhibiting activity | NOVARTIS AG (CH) | 2011-10-11 | — | — | US | disclosed |
| US-20110130399-A1 | Phthalazine Derivatives with Angiogenesis Inhibiting Activity | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| US-20090076003-A1 | Phthalazine Derivatives with Angiogenesis Inhibiting Activity | NOVARTIS AG | 2009-03-19 | — | — | US | disclosed |
| EP-1387836-B1 | PHTHALAZINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076003-A1 | Phthalazine Derivatives with Angiogenesis Inhibiting Activity | KDR, FLT1, FLT4 | KDM4E 2454/4885HSD17B10 1853/4885GRM4 3379/4885 |
| US-20110130399-A1 | Phthalazine Derivatives with Angiogenesis Inhibiting Activity | KDR, FLT1, FLT4 | KDM4E 2688/4885HSD17B10 1972/4885GRM4 2560/4885 |
| US-20040180899-A1 | Phthalazine derivatives with angiogenesis inhibiting activity | VEGFA, NR5A1, PGF | KDM4E 1776/4885HSD17B10 953/4885GRM4 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.